SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Perspective Chapter: Engineering Secretory IgA against Infectious Diseases

Falci Finardi, N; Teh, AYH; Ma, JK-C (2023) Perspective Chapter: Engineering Secretory IgA against Infectious Diseases. In: Immunosuppression and Immunomodulation [Working Title]. (eds Tyagi, RK; Sharma, P; Sharma, P.) IntechOpen. DOI: https://doi.org/10.5772/intechopen.108426
SGUL Authors: Teh, Yi Hui

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (251kB) | Preview

Abstract

The dawn of antibody therapy was heralded by the rise of IgG therapeutics. However, other antibody classes are at our disposal—one of the most exciting is IgA and is the most abundant antibody class within humans. Unlike IgG, it is uniquely specialized for mucosal applications due to its ability to form complex Secretory IgA (SIgA) molecules. Since the mucosa is constantly exposed to potential infectious agents, SIgA is pivotal to disease prevention as an important component of the mucosal barrier. Compared to IgG, SIgA has proven superior effectiveness in mucosal surfaces, such as the airway epithelium or the harsh gut environment. Despite this, hurdles associated with low yield and challenging purification have blocked SIgA therapeutic advancement. However, as a result of new antibody engineering strategies, we are approaching the next generation of (IgA-based) antibody therapies. Strategies include fine-tuning SIgA assembly, exploring different production platforms, genetic engineering to improve purification, and glycoengineering of different components. Due to its stability in mucosal environments, SIgA therapeutics would revolutionize passive mucosal immunotherapy—an avenue still underexploited by current therapeutics. This chapter will focus on the current perspectives of SIgA engineering and explore different approaches to unlocking the full therapeutic potential of SIgAs.

Item Type: Book Section
Additional Information: © 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Editors: Tyagi, RK; Sharma, P; Sharma, P
ISBN: 978-1-83768-072-6, 978-1-83768-071-9, 978-1-83768-073-3
Dates:
DateEvent
12 July 2023Published
11 November 2022Published Online
Publisher License: Creative Commons: Attribution 3.0
Projects:
Project IDFunderFunder ID
760331Horizon 2020http://dx.doi.org/10.13039/501100007601
774078Horizon 2020http://dx.doi.org/10.13039/501100007601
URI: https://openaccess.sgul.ac.uk/id/eprint/115134
Publisher's version: https://doi.org/10.5772/intechopen.108426

Actions (login required)

Edit Item Edit Item